Anthem Biosciences Ltd files Q1 FY2026 consolidated financial results

What Anthem Biosciences announced

Anthem Biosciences Ltd submitted a press release titled "Press Release on Consolidated Financial Results for the quarter ended June 30, 2026" on 21 July 2026. The filing, made under Regulation 30 (LODR), provides the company’s consolidated financial performance for the first quarter of its fiscal year ending 30 June 2026.

Filing details and regulatory context

• Filing date: 21 July 2026, 11:24 UTC
• Exchange: Bombay Stock Exchange (BSE)
• BSE code: 544449
• Regulation: 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR)
• Document type: Press release / media release (PDF attached to the filing)

The filing complies with SEBI’s mandate that listed entities disclose quarterly results within 45 days of the quarter’s end. No specific financial numbers are reproduced in the brief description; they are expected to be detailed in the accompanying PDF.

Key facts at a glance

Why this matters for investors

The filing confirms that Anthem Biosciences has met its statutory reporting obligations, providing transparency into its quarterly performance. While the summary does not disclose revenue, profit, or cash‑flow figures, investors can retrieve the full financial statements from the linked PDF. Timely compliance reduces regulatory risk and ensures that shareholders have access to the company’s operational metrics for the quarter.

Conclusion

Anthem Biosciences Ltd has formally disclosed its Q1 FY2026 consolidated results through a Regulation 30 filing on the BSE on 21 July 2026. Detailed financial numbers are contained in the attached press release PDF. Stakeholders should review the PDF for a complete view of the company’s performance and any accompanying management commentary.